Prexton Therapeutics SA
Records under this name other than the patents Prexton Therapeutics SA holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 6 of 6 · Back to Prexton Therapeutics SA
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,532,057 | Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia Lapsed on the fee record Ended Jan 14, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jan 14, 2024 | From the USPTO record |
| US 8,962,627 | Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors Lapsed on the fee record Ended Feb 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Feb 24, 2023 | From the USPTO record |
| US 10,059,671 | Positive Allosteric Modulators of MGLUR3 Lapsed on the fee record Ended Aug 28, 2022 · High confidence | Lapsed on the fee record | Ended Aug 28, 2022 | High confidence |
| US 10,017,521 | Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors Lapsed on the fee record Ended Jul 10, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jul 10, 2022 | From the USPTO record |
| US 9,879,004 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 Lapsed on the fee record Ended Jan 30, 2022 · High confidence | Lapsed on the fee record | Ended Jan 30, 2022 | High confidence |
| US 9,763,938 | Substituted Quinoxalines as Positive Allosteric Modulators of MGLUR4 Lapsed on the fee record Ended Sep 19, 2021 · Medium confidence | Lapsed on the fee record | Ended Sep 19, 2021 | Medium confidence |